October 6, 2021 7:58am

A follow-through session usually occurs into a rally “effort” however; the issue is low volume than the prior session’s volatility

News: Voyager Therapeutics (VYGR +$0.95 or +38.46% pre-open) an agreement through which Pfizer (PFE) may exercise options to license novel capsids generated from VYGR’s RNA-driven TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) screening technology as part of PFE’s efforts to develop, manufacture, and commercialize gene therapies, utilizing two undisclosed transgenes to treat certain neurologic and cardiovascular diseases.

Pre-open indications: 2 BUYs and 4 SELLs

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are DOWN -0.92% (-315 points), S&P futures are DOWN -1.10% (-48 point) and NASDAQ futures are DOWN -1.29% (-189 point)

 

U.S. stock futures pointed to a big decline Wednesday,

European stocks were sharply lower as all sectors and major bourses slid into negative territory,

Asia-Pacific stocks were mostly lower while Mainland Chinese markets remained closed for the holidays.

 

Henry’omics:

Indexes finished somewhat off highs while the stem, cell and gene therapy sector barely closed positive with volume on the light side.

As the small-cap Russell 2000 edged up 0.35%, just above its 200-day line and below its 50-day. Tuesday volume declined versus Monday, which isn't exactly inspiring. And it was just one day. Friday's low-volume rebound had some decent price gains, but those were wiped out on Monday.

 

Economic Data Docket: The ADP private payrolls report for September to be released. That will set the tone ahead of the closely followed nonfarm payrolls report on Friday from the Labor Department, which could determine how soon the Fed will begin removing policy stimulus.

 

If you didn’t remember what happen at Tuesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Q4: 1 positive and 2 negative closes

Q3/21:

  • September, 1 holiday, 10 positive and 10 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Maintaining SELL:

The “pump/promote” missed its “tikker” …

Tuesday closed down -$0.59 with to $3.04 with 957 shares traded after Monday closed up +$0.58 with 2,189 shares traded following Friday (10/41) closing up +$0.05 to $3.05 with 2,113 shares traded

The Biostage (BSTG) Chronicles: The Biostage (BSTG) Chronicles: An extrapolation from the WSJ as I question BSTG, “For years, U.S. regulators said they never got the transparency they needed into the auditing on Chinese companies because <read more> …  https://www.regmedinvestors.com/articles/12110

 

BUY:

Applied Genetic Technologies (AGTC) closed down -$0.07 to $2.63 after Monday’s $2.70 and last Friday’s $2.84, Monday’s $3.01, Tuesday’s $3.08 and Wednesday’s $3.12 with a positive +$0.02 or +0.76% pre-market indication.

Voyager Therapeutics (VYGR) closed down -$0.09 to $2.47 with a positive +$0.95 or +38.46% on news of an agreement through which Pfizer Inc (NYSE: PFE) may exercise options to license novel capsids generated from Voyager’s RNA-driven TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) screening technology as part of Pfizer’s efforts to develop, manufacture, and commercialize gene therapies, utilizing two undisclosed transgenes to treat certain neurologic and cardiovascular diseases.

 

SELL:

Intellia Therapeutics (NTLA) closed up +$2.98 to $129.76 after Monday’s -$7.28 to $126.78, Friday’s -$0.09 to $134.06, Thursday’s -$3.41 to $134.14 and last Wednesday’s -$1.85 to $137.56 with a negative -$0.22 or -0.17% pre-market indication.

MiMedx (MDXG) closed up +$0.16 to $5.86 and has a positive +$0.15 or -2.56% aftermarket indication.

Sangamo Therapeutics (SAGE) closed up +$0.04 to $8.85 after Monday’s $8.81 and last Friday’s $9.26, Monday’s $9.01, Tuesday’s $9.12 and Wednesday’s $9.48 with a negative -$0.31 or -3.50% pre-market indication.

 

 

The BOTTOM LINE: There's no need for investors to try to rush back into the sector.

if the sector has any “legs”, there will be plenty of opportunities for investors after a confirmed rally.

There is still a lot of risk out-there and sentiment is as lonely as volatility. If you still have an appetite for stocks, keep your positions small and be ready to exit quickly.

Not yielding in my thoughts, I keep reinforcing that increased stock market volatility suppresses the stem, cell and gene therapy sector.

I do not believe the recent bout of share pricing depression will lead to buyable equities and maintain the stance … not to buy into many of the weaknesses.

Theme is uncertainty, more likely to me: skepticism …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.